Alina Boteanu

Alina Boteanu

Auto-generated profile, based on publicly available information

Alina Boteanu

Rheumatology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2024 in Rheumatology
Verified
Journal Article
Open access
PDF file
HBHermine I Brunner
Hermine I Brunner
NRNicolino Ruperto
Nicolino Ruperto
ARAthimalaipet V Ramanan
Athimalaipet V Ramanan
GHGerd Horneff
Gerd Horneff
KMKirsten Minden
Kirsten Minden
JDJason Dare
Jason Dare
Objective: To investigate the safety and efficacy of subcutaneous tocilizumab (SC-TCZ) treatment in a long-term extension (LTE) of clinical trials in polyarticular or systemic juvenile idiopathic arthritis (pJIA or sJIA). Methods: Patients with pJIA or sJIA from two open-label, 52-week phase 1b core trials of SC-TCZ who had adequate response per investigator assessment entered the LTE and continued SC-TCZ treatment according to body weight–based dosing regimens until commercial availability or up to 5 years. Pharmacokinetics, pharmacodynamics, and efficacy were assessed for up to 3 years, and safety for up to 5 years in the LTE. Results: Forty-four patients with pJIA and 38 patients with sJIA entered the LTE. Tocilizumab trough concentrations were maintained within the range expected to provide clinical benefit (mean values: pJIA, ∼10 μg/ml; sJIA, ∼75 μg/ml over 3 years). Pharmacodynamic parameters (interleukin-6, soluble interleukin-6 receptor, erythrocyte sedimentation rate, C-reactive protein) were maintained throughout the LTE at levels achieved in the core trials. Inactive disease per American College of Rheumatology provisional criteria was reported for 90% (17/19) and 53% (8/15) of patients with pJIA and 91% (10/11) and 92% (12/13) of patients with sJIA in the <30 and ≥30 kg body weight groups, respectively. Serious adverse events in the LTE were reported in six patients with pJIA (13.6%; five serious infections) and five patients with sJIA (13.2%; one serious infection). Conclusion: Patients with pJIA or sJIA experienced long-term disease control with SC-TCZ treatment. Long-term safety was consistent with the known tocilizumab safety profile. Clinical trial registration: clinicaltrials.gov, NCT02165345

27 November 2021 in Pediatric Rheumatology
Verified
Journal Article
Open access
PDF file
DCDaniel Clemente
Daniel Clemente
CUClara Udaondo
Clara Udaondo
JIJaime de Inocencio
Jaime de Inocencio
Juan J. NietoJuan J. Nieto
Juan J. Nieto
PRPilar Galán del Río
Pilar Galán del Río
ABAlina Boteanu
Alina Boteanu
Background: This study aimed to assess the baseline characteristics and clinical outcomes of coronavirus disease 2019 (COVID-19) in pediatric patients with rheumatic and musculoskeletal diseases (RMD) and identify the risk factors associated with symptomatic or severe disease defined as hospital admission, intensive care admission or death. Methods: An observational longitudinal study was conducted during the first year of the SARS-CoV-2 pandemic (March 2020–March 2021). All pediatric patients attended at the rheumatology outpatient clinics of six tertiary referral hospitals in Madrid, Spain, with a diagnosis of RMD and COVID-19 were included. Main outcomes were symptomatic disease and hospital admission. The covariates were sociodemographic and clinical characteristics and treatment regimens. We ran a multivariable logistic regression model to assess associated factors for outcomes. Results: The study population included 77 pediatric patients. Mean age was 11.88 (4.04) years Of these, 30 patients (38.96%) were asymptomatic, 41 (53.25%) had a mild-moderate COVID-19 and 6 patients (7.79%) required hospital admission. The median length of hospital admission was 5 (2–20) days, one patient required intensive care and there were no deaths. Previous comorbidities increased the risk for symptomatic disease and hospital admission. Compared with outpatients, the factor independently associated with hospital admission was previous use of glucocorticoids (OR 3.51; p = 0.00). No statistically significant risk factors for symptomatic COVID-19 were found in the final model. Conclusion: No differences in COVID-19 outcomes according to childhood-onset rheumatic disease types were found. Results suggest that associated comorbidities and treatment with glucocorticoids increase the risk of hospital admission.

21 May 2021 in Clinical and Experimental Rheumatology
Verified
Journal Article
Open access
LRLeyre Riancho-Zarrabeitia
Leyre Riancho-Zarrabeitia
VMVictor Manuel Martinez-Taboada
Victor Manuel Martinez-Taboada
IRIñigo Rúa-Figueroa
Iñigo Rúa-Figueroa
FAFernando Alonso
Fernando Alonso
MGMaría Galindo-Izquierdo
María Galindo-Izquierdo
JRJosé M. Pego Reigosa
José M. Pego Reigosa
Full Papers; Authors: L. Riancho-Zarrabeitia, V.M. Martínez-Taboada, I. Rúa-Figueroa, F. Alonso, M. Galindo-Izquierdo, J. Ovalles, A. Olivé-Marqués, N. Mena Vázquez, J. Calvo-Alén, R. Menor Almagro, E. Tomero Muriel, E. Uriarte Isacelaya, A. Boteanu, M. Andres, M. Freire González, G. Santos Soler, M.E. Ruiz-Lucea, M. Ibáñez-Barceló, I. Castellví, C. Galisteo, V. Quevedo Vila, E. Raya, J. Narváez, L. Expósito, J.A. Hernández Beriaín, L. Horcada, E. Aurrecoechea, J.M. Pego Reigosa

19 March 2022 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
AGAntía García-Fernández
Antía García-Fernández
ABAndrea Briones-Figueroa
Andrea Briones-Figueroa
LCLaura Calvo-Sanz
Laura Calvo-Sanz
ÁAÁfrica Andreu-Suárez
África Andreu-Suárez
ABAlina Boteanu
Alina Boteanu

11 April 2016 in Reumatología Clínica
Verified
Journal Article
Closed access
CACARLOS ANTONIO GUILLEN ASTETE
CARLOS ANTONIO GUILLEN ASTETE
ABAlina Boteanu
Alina Boteanu
MBMaría Ángeles Blázquez-Cañamero
María Ángeles Blázquez-Cañamero
MVMaría Villarejo-Botija
María Villarejo-Botija

22 May 2023 in Pediatric Dermatology
Verified
Journal Article
Closed access
BNBelen de Nicolas-Ruanes
Belen de Nicolas-Ruanes
LRLuis Requena
Luis Requena
ABAlina‐Lucica Boteanu
Alina‐Lucica Boteanu
ANAntonia Navarro‐Cantero
Antonia Navarro‐Cantero
BPBibiana Perez‐Garcia
Bibiana Perez‐Garcia